Tue, Sep 2, 2014, 5:23 AM EDT - U.S. Markets open in 4 hrs 7 mins

Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

  • recognizer007 recognizer007 Oct 30, 2013 8:20 AM Flag

    Bottom,Revs and News,What else

    ya all shorties need to cover away.News shows how serious OPKO is in the Prostate Business.
    In connection with the financing transaction, the Company has entered into an agreement with OPKO, pursuant to which OPKO has been granted a right of first negotiation, providing exclusive rights to negotiate with Arno for a limited period regarding any potential strategic transactions that Arno's Board of Directors elects to pursue. In addition, OPKO shall have the right to designate one individual to serve as an observer to all meetings of Arno's Board of Directors.

    Dr. Phillip Frost, OPKO's Chairman and Chief Executive Officer, said, "Our team at OPKO regularly reviews what we consider exciting healthcare investments that offer scientific opportunities in areas of unmet medical need. Our process for selection is diligent. We were attracted to Arno based on the potential of onapristone and its progress towards the clinic. Dr. Belldegrun and the Arno development team have constructed a thoughtful clinical strategy intelligently incorporating a fully developed companion diagnostic. We look forward to expanding our relationship with Arno as the Company continues to advance the compound's clinical development."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The Scripps Institute news is amazing too.
      FierceBiotech Research
      Special Report: CNS Disease - The Scripps Research Institute/Opko Health
      October 29, 2013
      "If scientists are successful, SR-3306 could be the first compound of its kind to protect the brain from the devastating consequences of Parkinson's disease. "

      "In February, LoGrasso and his colleagues published new data on SR-3306, showing that the compound also protects tissue in animals after major ischemic events, such as heart attack and stroke."

      Sentiment: Strong Buy

    • The Scripps Institute news is amazing too.
      FierceBiotech Research
      Special Report: CNS Disease - The Scripps Research Institute/Opko Health
      October 29, 2013
      "If scientists are successful, SR-3306 could be the first compound of its kind to protect the brain from the devastating consequences of Parkinson's disease. "

      "In February, LoGrasso and his colleagues published new data on SR-3306, showing that the compound also protects tissue in animals after major ischemic events, such as heart attack and stroke."

      Sentiment: Strong Buy

 
OPK
8.90+0.04(+0.45%)Aug 29 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exelixis, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Criteo SA
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT